Figure 5.

MSC-exos ameliorated the activation of UPR under the AGEs treatment. The MSC-exos group was cotreated with AGEs (200 μg/mL) and MSC-exos (100 μg/mL). (A) The protein expression levels of p-PERK, PERK, ATF6, p-IREα, IREα, XBP1, ATF4, and CHOP were measured by western blot analysis. GAPDH was used as an internal control. (B) Quantitative analysis of relative protein levels for p-PERK, ATF6, p-IREα, XBP1, ATF4, and CHOP. (C-E) The transcriptional levels of XBP1 (C), ATF4 (D) and CHOP (E) were analyzed by qRT-PCR. Data were presented as the mean ± SD. *P < 0.05 vs. control group, ^#P < 0.05 vs. AGEs group.